{"id":"NCT03434041","sponsor":"Janssen Research & Development, LLC","briefTitle":"A Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Participants With Treatment-resistant Depression","officialTitle":"A Randomized, Double-blind, Multicenter Active-controlled Study to Evaluate the Efficacy, Pharmacokinetics, Safety and Tolerability of Flexible Doses of Intranasal Esketamine Plus an Oral Antidepressant in Adult Subjects With Treatment-resistant Depression","status":"COMPLETED","phase":"PHASE3","dates":{"start":"2018-05-25","primaryCompletion":"2021-04-13","completion":"2021-04-13","firstPosted":"2018-02-15","resultsPosted":"2022-05-24","lastUpdate":"2025-04-29"},"enrollment":252,"design":{"allocation":"RANDOMIZED","model":"PARALLEL","masking":"DOUBLE","primaryPurpose":"TREATMENT"},"conditions":["Depressive Disorder, Treatment-Resistant"],"interventions":[{"type":"DRUG","name":"Esketamine 56 mg","otherNames":[]},{"type":"DRUG","name":"Esketamine 84 mg","otherNames":[]},{"type":"DRUG","name":"Placebo","otherNames":[]},{"type":"DRUG","name":"Duloxetine (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Escitalopram (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Sertraline (Oral Antidepressant)","otherNames":[]},{"type":"DRUG","name":"Venlafaxine Extended Release (XR) (Oral Antidepressant)","otherNames":[]}],"arms":[{"label":"Intranasal Esketamine plus Oral Antidepressant","type":"EXPERIMENTAL"},{"label":"Oral Antidepressant plus Intranasal Placebo","type":"ACTIVE_COMPARATOR"}],"summary":"The purpose of this study is to evaluate the efficacy of switching adult participants with treatment-resistant depression (TRD) from a prior antidepressant treatment (to which they have not responded) to flexibly dosed intranasal esketamine (56 milligram \\[mg\\] or 84 mg) plus a newly initiated oral antidepressant compared with switching to a newly initiated oral antidepressant (active comparator) plus intranasal placebo, in improving depressive symptoms. Efficacy will be assessed by the change from baseline in the Montgomery Asberg Depression Rating Scale (MADRS) total score from Day 1 (before randomization) to the end of the 4-week double-blind treatment phase.","primaryOutcome":{"measure":"Change From Baseline in Montgomery Asberg Depression Rating Scale (MADRS) Total Score to the End of Double-blind Treatment Phase (Day 28)","timeFrame":"Baseline up to end of the double-blind treatment phase (Day 28)","effectByArm":[{"arm":"Intranasal Esketamine + Oral Antidepressant (AD)","deltaMin":-10.1,"sd":10.8},{"arm":"Intranasal Placebo + Oral AD","deltaMin":-8.1,"sd":10.26}],"pValues":[{"comp":"OG000","p":"0.123"}]},"eligibility":{"minAge":"18 Years","sex":"ALL","healthyVolunteers":false,"inclusionCount":4,"exclusionCount":1},"locations":{"siteCount":30,"countries":["United States","China"]},"refs":{"pmids":[],"seeAlso":[]},"adverseEventsSummary":{"seriousAny":{"events":3,"n":126},"commonTop":["Dizziness","Dissociation","Nausea","Blood Pressure Increased","Headache"]}}